These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 14746530)

  • 1. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors.
    Rowinsky EK
    Annu Rev Med; 2004; 55():433-57. PubMed ID: 14746530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors.
    Ritter CA; Arteaga CL
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):3-11. PubMed ID: 12644979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia.
    Arteaga CL
    J Clin Oncol; 2001 Sep; 19(18 Suppl):32S-40S. PubMed ID: 11560969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ErbB-targeted therapeutic approaches in human cancer.
    Arteaga CL
    Exp Cell Res; 2003 Mar; 284(1):122-30. PubMed ID: 12648471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia.
    Arteaga CL
    Semin Oncol; 2002 Oct; 29(5 Suppl 14):3-9. PubMed ID: 12422308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational bases for the development of EGFR inhibitors for cancer treatment.
    Bianco R; Gelardi T; Damiano V; Ciardiello F; Tortora G
    Int J Biochem Cell Biol; 2007; 39(7-8):1416-31. PubMed ID: 17596994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
    Baselga J; Arteaga CL
    J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB; Hynes NE; Lane HA
    Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ErbB/HER receptor protein-tyrosine kinases and cancer.
    Roskoski R
    Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium.
    Fuller SJ; Sivarajah K; Sugden PH
    J Mol Cell Cardiol; 2008 May; 44(5):831-54. PubMed ID: 18430438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase receptors as attractive targets of cancer therapy.
    Bennasroune A; Gardin A; Aunis D; Crémel G; Hubert P
    Crit Rev Oncol Hematol; 2004 Apr; 50(1):23-38. PubMed ID: 15094157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of ErbB1, ErbB2, and their Dual Targeting Using Small Molecules and Natural Peptides: Blocking EGFR Cell Signaling Pathways in Cancer: A Mini-Review.
    Patnaik SK; Chandrasekar MJN; Nagarjuna P; Ramamurthi D; Swaroop AK
    Mini Rev Med Chem; 2022 Oct; 22(22):2831-2846. PubMed ID: 35549881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into anti-HER-2 receptor monoclonal antibody research.
    Kumar R; Mandal M; Vadlamudi R
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):84-91; discussion 92-100. PubMed ID: 11236033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting epidermal growth factor receptor in head and neck cancer.
    Ford AC; Grandis JR
    Head Neck; 2003 Jan; 25(1):67-73. PubMed ID: 12478546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells.
    Zi X; Grasso AW; Kung HJ; Agarwal R
    Cancer Res; 1998 May; 58(9):1920-9. PubMed ID: 9581834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.
    Mendelsohn J; Baselga J
    J Clin Oncol; 2003 Jul; 21(14):2787-99. PubMed ID: 12860957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor targeting in cancer.
    Mendelsohn J; Baselga J
    Semin Oncol; 2006 Aug; 33(4):369-85. PubMed ID: 16890793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy.
    Friedländer E; Arndt-Jovin DJ; Nagy P; Jovin TM; Szöllosi J; Vereb G
    Cytometry A; 2005 Oct; 67(2):161-71. PubMed ID: 16163699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signal transduction and oncogenesis by ErbB/HER receptors.
    Marmor MD; Skaria KB; Yarden Y
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):903-13. PubMed ID: 14967450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies specific for peptide epitopes of the epidermal growth factor receptor's extracellular domain.
    Baron AT; Huntley BK; Lafky JM; Reiter JL; Liebenow J; McCormick DJ; Ziesmer SC; Roche PC; Maihle NJ
    Hybridoma; 1997 Jun; 16(3):259-71. PubMed ID: 9219036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.